Clinical Trial Update: Evaluate the Safety, Tolerability, Immunogenicity and Efficacy of UB-311 in Mild Alzheimer's Disease (AD) Patients [Phase 2]

View source ↗

Summary

Phase 2 trial evaluation of UB-311 in mild Alzheimer's disease completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• UB 311

Snippet

Sponsor: United Neuroscience Ltd. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-01-13